|
|
C F S
- Information International 37 kDa RNase
L
|
|
|
The importance of the Rnase pathway
Antiviral pathway deregulation
of CFS induces NO production in immune cells that precludes a resolution of
the Inflammatory response, fremont.etal06.txt,
fremont.etal06.pdf. Intracellular immune
dysfunction in ME/CFS: state of the art and therapeutic implications, nijs.fremont07.txt. Unravelling
intracellular immune dysfunctions in CFS: interactions between protein kinase
R activity, RNase L cleavage and elastase activity, and their clinical
relevance, meeus.etal08.txt. Patents relating to
the above findings by the Belgian researchers, patents, CFS, 2002. Diagnostic methods for measuring elastase
activity levels, patent.elastase.act06.txt. 37 kDa protein - characterization
The ongoing process of
characterizing the 37 kDa protein by sophisticated biochemical methods, Shetzline & Suhadolnik,
2001, Shetzline & Suhadolnik, 2001 (pdf). More basic
biochemistry by the Belgian team on the RNase-L split products, Englebienne et al., 2001., and on the
characterization,
Shetzline et al., 2002. Further evidence for the 37 kDa being a
truncated form of the native 2-5A dependent ribonuclease L (RNase L),
generated by an increased proteolytic activity in CFS cell extracts, Demettre et al., 2002. A 2003-review, englebienne03.txt and an editorial about CFS and Rnase L, editorial.jcfs03.txt. fremont.etal05.txt,
fremont.etal05.pdf : 2',5'-Oligoadenylate
size is critical to protect RNase L against proteolytic cleavage in CFS. Apoptosis and RNase L activation
Downregulation of the RNase L
enzyme cascade, possibly caused by RNA segments, resulting in a defect in the
normal apoptosis (cell suicide) process, is found both in CFS and MS
cells, Englebienne et al., 2001. 37 kDa protein and Ampligen
There are results indicating
that patients who have the 37 kDa RNaseL, besides having 'a CFS marker', also
benefit the most from Ampligen treatment, De Meirleir et al., 2000, De Meirleir et al., 2000 (full paper). RNaseL and Mycoplasma
Two papers were presented in
Sydney, 2001 linking RNaseL and mycoplasma infection, De Meirleir et al., 2001 and Nijs et al., 2001. The latter research group has published
more details on their studies, nijs.etal03.txt. RNaseL and a Disease Model
A disease model for CFS
involving RnaseL,
Mc Gregor et al., 2001. Contrary to this view, Dr W. Behan states
that CFS is not a simple viral disease, and tests for acute activation of the
antiviral pathway leads nowhere,
Behan et al., 2001. Comparing physical performance and test
results for RNase activation, found no simple correlation, Snell et al., 2002. Japanese researchers have
studied these complicated enzymatic processes and found correlation between
Coxiella virus infection in CFS and the enzyme, 2`, 5`-oligoadenylate
synthetase, ikuta.etal03.pdf. An overview
of the evidence addressing the impairments of the 2'-5' oligoadenylate (2-5
A) synthetase/RNase L pathway in CFS patients, nijs.demeirleir05.txt. Rnase L - G-Actin-splitproduct - a Serum marker for
CFS ?
The Belgian research team
introduced a possible serum marker for increased RNase activity, the split
product of G-actin,
Roelens et al., 2001. In
2002 these researchers presented a book on RNase and CFS, book, De Meirleir, 2002, and a
commercial test for CFS, the detection of G-actin fragments in serum, based
on the above findings,
test, G actin, 2002. A list of antibiotics to be
included in the treatment regime has also been patented, antibiotics.list.deMeileir03.txt. A study from the US disproved
specific RNAse findings in CFS,
Vernon et al., 2002 (short), Vernon et al., 2002. A recent paper found the RNaseL test to be able to
distinguish CFS from controls,
Tiev et al., 2003 (short) Tiev
et al., 2003 (paper) Tiev
et al., 2003 (pdf). Examination of the relationship between clinical and
functional characteristics, immune abnormalities and status of the RNase L
pathway in CFS compared with healthy control and depression control populations,
supported the cytokine/immune activation model in a well-characterized CFS
patient group, suhadolnik.etal04.txt, suhadolnik.etal04.pdf. Micro RNA - a new player on the Scene
New information on this
interesting topic, news.microrna05.txt. |
|
Index Welcome CFS
case def. Prevalence Prognosis Brain
Inflam Post-Polio Hypotheses This
website is 100% non-commercial and independent of associations
and public authorities. |
|